Kevin J. Fowler
gratefull080504.bsky.social
Kevin J. Fowler
@gratefull080504.bsky.social
Consultant, The Voice of the Patient;COIs: Alexion, Bayer, Biogen, Dimerix, eGenesis, Enyo, Maze Therapeutics MediBeacon, Memo Therapeutics, Phreesia, ProKidney, Purespring Therapeutics , Travere https://www.linkedin.com/in/kevinjohnfowler/
Thank you very much.
August 17, 2025 at 12:15 AM
Thank you Eric for taking the time to read the article. As I point out in the article, it is time for the transplant community to acknowledge we need to move towards improving QOL and participation in life. Survival is not enough. You understand the issue completely with home dialysis.
May 15, 2025 at 5:49 PM
Happy to have a discussion on the subject with you. I firmly believe QOL + participation in life is where the community should prioritize.
May 15, 2025 at 5:08 PM
I completely agree with your statement. I think the implementation of PROMs allow patients to be heard. Speaking for myself, I have often felt unheard. When patients felt heard, I think the process becomes easier for both parties.
May 15, 2025 at 5:02 PM
Thank you very much for reading the article.
May 15, 2025 at 4:56 PM
Sad but true. #nephjc
April 30, 2025 at 1:58 AM
Agreed, and the further phenotyping will help lead to treatments for AMR. Kidney transplant physicians need more tools to preserve kidney transplants. The SONG initiative showed that kidney transplant recipients feared going on dialysis more than dying #nephjc
April 30, 2025 at 1:53 AM
and resarch that will lead to treatments that are FDA approved. #nephjc
April 30, 2025 at 1:49 AM
FSGS is now viewed as a continuum. I think rejection is moving in that direction as well. It is a mult-factorial issue that needs to be address in a similar manner. #nephjc
April 30, 2025 at 1:47 AM
Yes. #nephjc
April 30, 2025 at 1:43 AM
Good question that I hope is answered with future research. #nephjc
April 30, 2025 at 1:43 AM
Exactly. It is beginning to occur with IgAN + it is really need in kidney transplantation. #nephjc
April 30, 2025 at 1:38 AM
I will add another hopeful thought. Some of the medications approved for DKD are now being studied in kidney transplantation. They have anti-inflammatory properties that may dampen the inflammatory cascade. #nephjc
April 30, 2025 at 1:37 AM
There is no consensus. Some programs do DSA testing for high risk patients, some for cause, and some annually. I believe the lack of FDA approved treatments has result in a lack of consensus. #nephjc
April 30, 2025 at 1:34 AM
A very important kidney transplant precision study. Understand the various phenotypes + deliver targeted effective treatments #nephjc
April 30, 2025 at 1:31 AM
I wish surveillance DSA testing was done more often. It doesn't identify all of the problems but it is a good start. #nephjc
April 30, 2025 at 1:27 AM
U of Wisconsin represented the US for adult recipients. Pediatric recipients were included as well. #nephjc
April 30, 2025 at 1:23 AM
It is my theory that it does. #nephjc
April 30, 2025 at 1:21 AM
I have seen many friends lose their kidney transplants prematurely. None of the current treatments in the US are FDA approved. Moreover, generally peaking recipients don't receive AMR education. #nephjc
April 30, 2025 at 1:19 AM
Speaking from professional experience surveillance DSA testing is not done routinely. I now have a annual DSA test surveillance test #nephjc
April 30, 2025 at 1:15 AM
I will add this for discussion. The role of inflammation is very important. I work out routinely on my Elliptical since my transplant. I wish there were studies about the role of reducing inflammation + whether that may reduce the inflammation process #Nephjc
April 30, 2025 at 1:13 AM
I am a fan of understanding it so that treatments can be found for AMR #nephjc
April 30, 2025 at 1:08 AM
I have. Very important work to help strategy populations at risk + to develop AMR treatments #nephjc
April 30, 2025 at 1:07 AM